Intra Aortic Balloon Pump IABP Sales

Intra Aortic Balloon Pump IABP Sales Market Outlook

As of 2023, the global Intra Aortic Balloon Pump (IABP) market is estimated to be valued at approximately $450 million and is projected to grow at a compound annual growth rate (CAGR) of around 5.8% from 2025 to 2035. This growth can be attributed to the increasing incidence of cardiovascular diseases, the rising number of high-risk cardiac procedures, and advancements in IABP technology that improve patient outcomes. Moreover, the growing geriatric population and the subsequent rise in demand for cardiac interventions are significant contributors. The market is also experiencing enhanced investment in healthcare infrastructure, particularly in emerging economies, which is expected to further stimulate demand for IABP systems.

Growth Factor of the Market

The growth of the Intra Aortic Balloon Pump (IABP) market is primarily driven by the increasing prevalence of cardiovascular diseases, which is one of the leading causes of morbidity and mortality globally. With lifestyle changes, such as poor diet and lack of physical activity, cardiovascular conditions are on the rise, necessitating advanced medical interventions. Furthermore, the aging population is more susceptible to cardiac ailments, thereby increasing the demand for IABP devices. Technological advancements, including the introduction of more efficient and user-friendly IABP systems, have also contributed significantly to market growth. Additionally, the expansion of healthcare facilities and the rising number of cardiac surgeries and procedures are expected to amplify the demand for these life-saving devices. The focus on patient safety and improved clinical outcomes is driving hospitals and clinics to invest in state-of-the-art equipment, including IABPs, thus positively impacting market growth. Lastly, government initiatives aimed at improving healthcare access and funding for cardiovascular research play a pivotal role in enhancing the market landscape.

Key Highlights of the Market

• Significant growth anticipated due to rising cardiovascular disease prevalence.
• Technological advancements enhancing patient outcomes and device efficacy.
• Increased healthcare funding and expansion of healthcare facilities.
• Aging population contributing to higher demand for advanced cardiac interventions.
• Focus on patient-centered care driving investments in modern IABP systems.

By Product Type

Fiber Optic IABP:

Fiber Optic Intra Aortic Balloon Pumps are gaining traction due to their lightweight design and the ability to provide real-time monitoring of pressure through fiber optic technology. These devices enhance the accuracy of hemodynamic measurements, allowing for better management of patients in critical care settings. Their design minimizes the risk of complications and provides improved durability compared to traditional devices. The integration of fiber optics in IABPs also allows for enhanced communication between the pump and the monitoring systems, ensuring that healthcare providers receive immediate insights into the patient's condition. This type of IABP is particularly advantageous in high-risk surgical procedures, where precision and rapid response times are crucial.

Fluid-Filled IABP:

Fluid-Filled IABPs are one of the most commonly used types in clinical practice. These devices utilize a fluid-filled balloon that inflates and deflates in synchrony with the patient's cardiac cycle, thereby reducing myocardial oxygen demand and improving coronary perfusion. Their proven efficacy in treating cardiogenic shock and supporting high-risk cardiac surgeries has led to widespread adoption in hospitals. The ease of use and cost-effectiveness of fluid-filled IABPs make them a preferred choice for many healthcare facilities. However, challenges such as the risk of balloon rupture and the need for frequent monitoring may limit their use in certain patient populations, pushing manufacturers towards innovation in this space to enhance safety and reliability.

Helium-Filled IABP:

Helium-Filled IABPs are characterized by their rapid inflation and deflation capabilities, which contribute to greater hemodynamic support for patients. The use of helium as a filling gas allows for faster response times and reduced risk of complications associated with fluid-filled devices. These pumps have been associated with lesser complications such as thrombus formation and embolism risks. As a result, helium-filled IABPs are often utilized in critical care settings where patient stability is paramount. However, the high costs associated with helium technology may limit their adoption in certain regions or healthcare settings, although their effectiveness in reducing myocardial workload is driving continued interest and investment.

Battery-Powered IABP:

Battery-Powered IABPs are becoming increasingly popular due to their portability and ease of use. These devices allow for mobility in patients, making them suitable for transport within and outside the hospital. The absence of cords and the compact design facilitate easier management in emergent situations or during transfers to different departments. Battery-operated systems are particularly valuable in setting up temporary support for unstable patients. However, maintaining battery life and ensuring reliable performance under continuous operation are critical considerations for healthcare providers. As technology advances, improvements in battery efficiency and device longevity are likely to enhance the appeal of battery-powered IABPs, especially in emergency and trauma settings.

Pneumatic IABP:

Pneumatic IABPs utilize compressed gas to inflate and deflate the balloon and have been a staple in cardiac support. These devices are known for their reliability and simplicity, making them a common choice in many healthcare settings. They provide effective counterpulsation support, thereby improving cardiac output and reducing the workload on the heart. Their long-standing presence in the market means there is a wealth of clinical experience and data supporting their use. However, advancements in technology and the emergence of alternative pump types may pose challenges in maintaining market share. Continuous innovation in pneumatic IABPs, focusing on enhancing usability and patient comfort, is crucial to ensure their relevance amid growing competition.

By Application

Cardiac Surgery:

Intra Aortic Balloon Pumps play a vital role in cardiac surgeries, where they are utilized to manage hemodynamics during high-risk procedures. By providing critical support, these devices help stabilize patients, allowing surgeons to perform complex operations with a reduced risk of complications. The use of IABPs in this setting has been shown to decrease mortality rates and improve outcomes, making them an essential tool in cardiothoracic surgery. As surgical techniques evolve and patient populations become more complex, the demand for effective hemodynamic support in cardiac surgery will continue to fuel market growth.

Cardiogenic Shock:

Cardiogenic shock represents a significant application area for Intra Aortic Balloon Pumps, as these devices can dramatically improve survival rates in patients experiencing this life-threatening condition. By augmenting cardiac output and improving coronary perfusion, IABPs serve as a bridge to recovery or more definitive surgical interventions like heart transplantation or ventricular assist devices. The increasing incidence of cardiogenic shock, particularly in patients with acute myocardial infarction, drives demand for IABPs, reinforcing their importance in emergency care and critical settings.

High-Risk PCI:

High-risk percutaneous coronary interventions (PCI) are another key application for IABP usage. These procedures often involve patients with significant comorbidities or severely compromised cardiovascular function, necessitating advanced support during the intervention. The use of IABPs in this context helps to mitigate the risks associated with high-stakes procedures by providing hemodynamic stability and improving outcomes. As the prevalence of coronary artery disease rises, the need for effective support during high-risk PCI will continue to drive the adoption of IABPs in catheterization labs.

Acute MI:

In the management of acute myocardial infarction (MI), Intra Aortic Balloon Pumps are utilized to enhance blood flow to the myocardium and alleviate ischemic symptoms. When implemented swiftly, IABPs can significantly improve patient outcomes by reducing the extent of myocardial damage. As awareness of the importance of rapid intervention in acute MI increases, the adoption of IABPs is expected to rise in emergency departments and hospitals nationwide. The robust evidence supporting their effectiveness in this application is likely to sustain market growth in the coming years.

Others:

The "Others" category encompasses a range of applications where Intra Aortic Balloon Pumps can be beneficial, including post-operative care in cardiac patients and stabilization of patients prior to surgical procedures. These devices may also be used in research and clinical trials exploring new indications for IABPs, contributing to the broader understanding of their potential benefits. As healthcare providers continue to explore innovative ways to improve patient care, the versatility of IABPs in various applications will likely create further opportunities in this segment of the market.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for Intra Aortic Balloon Pumps, accounting for a significant portion of the market share. Given the critical nature of the procedures in which IABPs are used, hospitals are continuously investing in advanced medical equipment to ensure optimal patient care. The presence of specialized cardiac units and emergency departments necessitates a consistent supply of IABPs to support patients during high-risk interventions. With increasing patient volumes and the demand for quality healthcare services, hospitals are expected to remain the dominant distribution channel for IABPs in the foreseeable future.

Cardiology Clinics:

Cardiology clinics are emerging as an important distribution channel for Intra Aortic Balloon Pumps, particularly as outpatient procedures gain traction. These clinics often cater to patients with chronic cardiovascular conditions who require ongoing management and treatment options. By incorporating IABPs into their offerings, cardiology clinics can enhance patient care by providing advanced support during procedures such as catheterizations and electrophysiological studies. The growth of outpatient care models and the shift towards non-hospital settings for cardiac interventions are likely to boost the demand for IABPs in these facilities, making them a key player in the distribution landscape.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are increasingly playing a role in the distribution of Intra Aortic Balloon Pumps, driven by the shift towards less invasive, outpatient surgical procedures. ASCs provide a cost-effective alternative to hospitals for elective surgery and acute interventions, thereby expanding access to IABPs in a variety of settings. These centers often cater to patients requiring timely procedures, and the availability of IABPs can enhance their ability to manage high-risk cases effectively. As outpatient services continue to expand, the significance of ASCs in the IABP distribution market will likely increase.

Others:

The "Others" category includes various specialized facilities, such as long-term acute care hospitals and rehabilitation centers, where Intra Aortic Balloon Pumps may also be utilized. While not the primary distribution channel, these facilities contribute to the overall market by ensuring that patients requiring ongoing cardiac support receive appropriate care. The diversification of healthcare settings and the development of new care models may see an increase in demand for IABPs in these less conventional environments, providing additional growth opportunities in the market.

By Material Type

Polyurethane:

Polyurethane is one of the predominant materials used in the manufacture of Intra Aortic Balloon Pumps, owing to its excellent biocompatibility and flexibility. This material allows for the production of balloons that can expand and contract quickly, making them ideal for providing effective counterpulsation support. Polyurethane’s durability enhances the overall performance of IABPs while minimizing the risk of rupture or leakage, which is critical in emergency situations. As manufacturers continue to innovate and improve material properties, polyurethane is expected to remain a key material in the production of IABPs, contributing to enhanced patient safety and device reliability.

Silicone:

Silicone is another important material type used in IABP manufacturing, known for its superior biocompatibility and low reactivity with bodily fluids. Silicone balloons are often preferred for their flexibility and ability to maintain structural integrity under varying pressure conditions. The use of silicone in IABPs can reduce the risk of immune reactions, making it a suitable choice for patients with a history of allergies or sensitivities. As the demand for safer and more effective medical devices grows, silicone's role in the IABP market is likely to expand, particularly as new formulations and designs are developed to meet evolving patient needs.

Latex:

Latex materials have traditionally been used in some Intra Aortic Balloon Pumps due to their elasticity and strength. However, the use of latex is declining in modern IABPs, primarily due to the rising incidence of latex allergies among patients and healthcare staff. While latex balloons can provide effective counterpulsation, the potential for allergic reactions poses significant risks. As healthcare providers prioritize patient safety and comfort, many manufacturers are moving towards alternative materials, such as polyurethane and silicone, which offer comparable performance without the associated risks of latex. The gradual phase-out of latex in IABP production signifies a broader trend in the industry towards safer materials.

Others:

The "Others" category encompasses various innovative materials and composites being explored for use in IABP production. As technology advances, manufacturers are investigating new materials that could enhance the performance and biocompatibility of IABPs. These materials may include advanced polymers and synthetic materials designed to optimize device efficacy while reducing the risk of complications. The growing emphasis on patient safety and comfort is driving research and development efforts in this area, and we can expect to see more diverse material offerings in the IABP market in the near future, expanding treatment options for healthcare providers.

By Region

The Intra Aortic Balloon Pump market exhibits noteworthy regional variations, with North America leading the market due to a well-established healthcare infrastructure and high prevalence of cardiovascular diseases. The North American market is anticipated to grow at a CAGR of 6.1% over the forecast period, driven by the increasing number of cardiac surgeries and widespread adoption of advanced medical devices in hospitals. The presence of major medical device manufacturers and ongoing innovations in IABP technology further bolster market growth in this region. The combination of advanced healthcare facilities and a growing geriatric population presents a conducive environment for the expansion of IABPs, reinforcing North America’s dominance in the global market landscape.

Europe holds the second-largest share in the Intra Aortic Balloon Pump market, supported by rising cardiac disease incidence and strong healthcare initiatives aimed at improving cardiovascular care. The European market is projected to witness steady growth, fueled by government investments in healthcare and the increasing adoption of IABP systems in hospitals and clinics. Additionally, the presence of key global players in the region contributes to technological advancements that improve device performance and patient safety. Other regions, such as Asia Pacific, Latin America, and the Middle East & Africa, are also witnessing growth, albeit at a slower pace, due to varying healthcare infrastructure levels and economic conditions. The Asia Pacific region, in particular, is expected to experience significant growth due to a burgeoning population, increasing prevalence of chronic diseases, and rising healthcare expenditure.

Opportunities

The growing focus on cardiovascular healthcare initiatives presents significant opportunities for the Intra Aortic Balloon Pump market. As governments and healthcare organizations prioritize the reduction of cardiovascular disease mortality rates, there will be increased investments in advanced medical technologies, including IABPs. The rise in research and development activities focused on enhancing the efficacy and safety of IABPs will likely lead to the introduction of innovative solutions that can address unmet clinical needs. Additionally, expanding healthcare access in emerging economies is creating new market opportunities. The demand for better cardiac care solutions in these regions underscores the potential for IABPs to play a pivotal role in improving patient outcomes, particularly in resource-limited settings. As awareness grows regarding the importance of timely intervention in cardiovascular conditions, the market for IABPs is expected to witness robust growth.

Another promising opportunity lies in the ongoing technological advancements in IABP systems that enhance their functionality and usability. Innovations such as remote monitoring capabilities, wireless technology, and integration with advanced imaging systems can drive adoption rates by providing healthcare providers with real-time data and insights into patient conditions. These advancements not only improve patient management but also streamline clinical workflows, thereby enhancing operational efficiency. Furthermore, the increasing trend toward outpatient care models creates opportunities for IABPs to be utilized in ambulatory surgical centers and cardiology clinics. This shift in care delivery can help mitigate hospital congestion and improve access to life-saving therapies for patients with cardiovascular diseases, ultimately fostering growth in the IABP market.

Threats

Despite the positive growth outlook, the Intra Aortic Balloon Pump market faces several threats that could hinder its expansion. One significant challenge is the stringent regulatory framework governing medical devices, which can delay product approvals and market entry for new innovations. Regulatory agencies require comprehensive clinical data to ensure safety and efficacy, which can prolong the development cycle and increase costs for manufacturers. This regulatory burden may deter small and medium-sized enterprises from entering the market, limiting competition and innovation. Additionally, the high costs associated with advanced IABP systems may restrict their adoption in cost-sensitive regions, particularly in developing countries where healthcare budgets are constrained, thus affecting overall market growth.

Another potential threat is the emergence of alternative technologies and devices that could replace or diminish demand for IABPs. For instance, novel cardiac support devices, such as impella pumps and ECMO systems, are gaining traction for their ability to provide reliable hemodynamic support during critical procedures. As these alternatives become more widely adopted, they may pose a significant competitive threat to traditional IABP systems. Furthermore, the increasing availability of minimally invasive surgical techniques may also impact the demand for IABPs in specific applications. Given the dynamic nature of the medical device landscape, manufacturers must remain vigilant and continuously innovate to address competitive pressures and market challenges.

Competitor Outlook

• Maquet Cardiovascular LLC
• Getinge AB
• ABIOMED, Inc.
• Teleflex Incorporated
• Boston Scientific Corporation
• Edwards Lifesciences Corporation
• Terumo Corporation
• LivaNova PLC
• Medtronic PLC
• CardiacAssist, Inc.
• JOTEC GmbH
• ReliantHeart, Inc.
• SynCardia Systems, LLC
• Novartis AG
• Philips Healthcare

The competitive landscape of the Intra Aortic Balloon Pump market is characterized by the presence of several key players striving to gain market share through innovation, strategic partnerships, and product differentiation. Major companies such as Maquet Cardiovascular LLC and Getinge AB lead the market with their advanced IABP products and comprehensive service offerings. These firms have established a strong foothold in the market through continuous investment in research and development, enabling them to introduce innovative solutions that meet the evolving needs of healthcare providers. Additionally, they leverage their extensive distribution networks to ensure widespread availability of their products across various regions.

Other notable players, such as Medtronic PLC and Boston Scientific Corporation, are focusing on expanding their portfolios through acquisitions and collaborations with emerging companies. This strategy allows them to enhance their technological capabilities and access new markets. For instance, Medtronic's acquisition of Mazor Robotics has augmented its presence in robotic-assisted surgical devices, which could complement its existing cardiovascular offerings. The emphasis on providing comprehensive solutions that integrate IABPs with other cardiac care technologies is expected to foster growth and enhance competitive positioning in the market.

Emerging companies, such as ReliantHeart, Inc. and CardiacAssist, Inc., are also contributing to the competitive landscape by introducing innovative IABP systems that focus on improving patient outcomes and device performance. These companies often target niche markets and specific clinical applications, allowing them to differentiate themselves from established players. As technology continues to advance, the competitive dynamics within the IABP market will evolve, with both established companies and newcomers striving to address unmet needs and capitalize on growth opportunities.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Getinge AB
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 JOTEC GmbH
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 LivaNova PLC
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 ABIOMED, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Medtronic PLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Philips Healthcare
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 ReliantHeart, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Terumo Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 CardiacAssist, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Teleflex Incorporated
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 SynCardia Systems, LLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Maquet Cardiovascular LLC
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Boston Scientific Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Edwards Lifesciences Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Intra Aortic Balloon Pump IABP Sales Market, By Application
    • 6.1.1 Cardiac Surgery
    • 6.1.2 Cardiogenic Shock
    • 6.1.3 High-Risk PCI
    • 6.1.4 Acute MI
    • 6.1.5 Others
  • 6.2 Intra Aortic Balloon Pump IABP Sales Market, By Product Type
    • 6.2.1 Fiber Optic IABP
    • 6.2.2 Fluid-Filled IABP
    • 6.2.3 Helium-Filled IABP
    • 6.2.4 Battery-Powered IABP
    • 6.2.5 Pneumatic IABP
  • 6.3 Intra Aortic Balloon Pump IABP Sales Market, By Material Type
    • 6.3.1 Polyurethane
    • 6.3.2 Silicone
    • 6.3.3 Latex
    • 6.3.4 Others
  • 6.4 Intra Aortic Balloon Pump IABP Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Cardiology Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Intra Aortic Balloon Pump IABP Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Intra Aortic Balloon Pump IABP Sales market is categorized based on

By Product Type

• Fiber Optic IABP
• Fluid-Filled IABP
• Helium-Filled IABP
• Battery-Powered IABP
• Pneumatic IABP

By Application

• Cardiac Surgery
• Cardiogenic Shock
• High-Risk PCI
• Acute MI
• Others

By Distribution Channel

• Hospitals
• Cardiology Clinics
• Ambulatory Surgical Centers
• Others

By Material Type

• Polyurethane
• Silicone
• Latex
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Maquet Cardiovascular LLC
• Getinge AB
• ABIOMED, Inc.
• Teleflex Incorporated
• Boston Scientific Corporation
• Edwards Lifesciences Corporation
• Terumo Corporation
• LivaNova PLC
• Medtronic PLC
• CardiacAssist, Inc.
• JOTEC GmbH
• ReliantHeart, Inc.
• SynCardia Systems, LLC
• Novartis AG
• Philips Healthcare